Skip to Content
MilliporeSigma
  • Structure-activity relationship and mechanism of action studies of manzamine analogues for the control of neuroinflammation and cerebral infections.

Structure-activity relationship and mechanism of action studies of manzamine analogues for the control of neuroinflammation and cerebral infections.

Journal of medicinal chemistry (2009-12-19)
Jiangnan Peng, Sucheta Kudrimoti, Sivaprakasam Prasanna, Srinivas Odde, Robert J Doerksen, Hari K Pennaka, Yeun-Mun Choo, Karumanchi V Rao, Babu L Tekwani, Vamsi Madgula, Shabana I Khan, Bin Wang, Alejandro M S Mayer, Melissa R Jacob, Lan Chun Tu, Jürg Gertsch, Mark T Hamann
ABSTRACT

Structure-activity relationship studies were carried out by chemical modification of manzamine A (1), 8-hydroxymanzamine A (2), manzamine F (14), and ircinal isolated from the sponge Acanthostrongylophora. The derived analogues were evaluated for antimalarial, antimicrobial, and antineuroinflammatory activities. Several modified products exhibited potent and improved in vitro antineuroinflammatory, antimicrobial, and antimalarial activity. 1 showed improved activity against malaria compared to chloroquine in both multi- and single-dose in vivo experiments. The significant antimalarial potential was revealed by a 100% cure rate of malaria in mice with one administration of 100 mg/kg of 1. The potent antineuroinflammatory activity of the manzamines will provide great benefit for the prevention and treatment of cerebral infections (e.g., Cryptococcus and Plasmodium). In addition, 1 was shown to permeate across the blood-brain barrier (BBB) in an in vitro model using a MDR-MDCK monolayer. Docking studies support that 2 binds to the ATP-noncompetitive pocket of glycogen synthesis kinase-3beta (GSK-3beta), which is a putative target of manzamines. On the basis of the results presented here, it will be possible to initiate rational drug design efforts around this natural product scaffold for the treatment of several different diseases.

MATERIALS
Product Number
Brand
Product Description

Supelco
Melting point standard 235-237°C, analytical standard
Pricing and availability is not currently available.
Sigma-Aldrich
Rifampicin, suitable for plant cell culture, BioReagent, ≥95% (HPLC), powder or crystals
Pricing and availability is not currently available.
Supelco
Caffeine solution, analytical standard, 1.0 mg/mL in methanol
Pricing and availability is not currently available.
Sigma-Aldrich
Rifampicin, ≥95% (HPLC), powder or crystals
Pricing and availability is not currently available.
Supelco
Melatonin Related Compound A, Pharmaceutical Secondary Standard; Certified Reference Material
Pricing and availability is not currently available.
Sigma-Aldrich
Quinine, 90%
Pricing and availability is not currently available.
Sigma-Aldrich
Caffeine, anhydrous, 99%, FCC, FG
Pricing and availability is not currently available.
Sigma-Aldrich
Caffeine, anhydrous, tested according to Ph. Eur.
Pricing and availability is not currently available.
Sigma-Aldrich
Quinine, suitable for fluorescence, anhydrous, ≥98.0% (dried material, NT)
Pricing and availability is not currently available.
Sigma-Aldrich
Ciprofloxacin, ≥98% (HPLC)
Pricing and availability is not currently available.
Supelco
Mettler-Toledo Calibration substance ME 18872, Caffeine, traceable to primary standards (LGC)
Pricing and availability is not currently available.
Sigma-Aldrich
Caffeine, BioXtra
Pricing and availability is not currently available.
Sigma-Aldrich
Caffeine, powder, ReagentPlus®
Pricing and availability is not currently available.
Sigma-Aldrich
Caffeine, meets USP testing specifications, anhydrous
Pricing and availability is not currently available.
Sigma-Aldrich
Caffeine, Sigma Reference Standard, vial of 250 mg
Pricing and availability is not currently available.
Sigma-Aldrich
5-Methoxytryptamine, 97%
Pricing and availability is not currently available.
5-Methoxytryptamine, British Pharmacopoeia (BP) Reference Standard
Pricing and availability is not currently available.